Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Apr;84(7):959–964. doi: 10.1054/bjoc.2001.1697

Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562

J M Sargent 1, C J Williamson 1, C Yardley 1, C G Taylor 1, K Hellmann 1
PMCID: PMC2363849  PMID: 11286477

Abstract

Dexrazoxane combined with doxorubicin (+ 5-fluorouracil + cyclophosphamide – the FAC regime) leads to a significant decrease in doxorubicin cardiotoxicity and a significant increase in median survival time for patients with advanced breast cancer responsive to FAC. The reason for this increase in survival may be due to interference with the mechanism involved in the emergence of multidrug resistance (MDR). In order to test this hypothesis, we induced resistance to doxorubicin in the K562 cell line by growing cells in increasing concentrations of doxorubicin (10–30 nM) in the presence and absence of dexrazoxane (20 nM). The doxorubicin sensitivity of all resultant sublines was measured using the MTT assay. Flow cytometry was used to assess the MDR1 phenotype, measuring P-glycoprotein expression with MRK 16 antibody and drug accumulation in the presence and absence of PSC 833 for functional P-glycoprotein. Long-term growth in doxorubicin increased the cellular resistance (IC 50) of K562 cells in a concentration-dependent manner (r2 = 0.908). Doxorubicin resistance was not induced in the presence of dexrazoxane (P< 0.0001) for several months. In parallel, the expression of functional P-glycoprotein was delayed after concomitant addition of dexrazoxane to the selecting medium (P< 0.001). Dexrazoxane did not act as a conventional modulator of P-glycoprotein. These results suggest that dexrazoxane may delay the development of MDR1, thus allowing responders to the FAC regime to continue to respond. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: dexrazoxane, doxorubicin, K562, drug resistance, MDR, P-glycoprotein

Full Text

The Full Text of this article is available as a PDF (156.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Advani R., Saba H. I., Tallman M. S., Rowe J. M., Wiernik P. H., Ramek J., Dugan K., Lum B., Villena J., Davis E. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood. 1999 Feb 1;93(3):787–795. [PubMed] [Google Scholar]
  2. Bordow S. B., Haber M., Madafiglio J., Cheung B., Marshall G. M., Norris M. D. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res. 1994 Oct 1;54(19):5036–5040. [PubMed] [Google Scholar]
  3. Chaudhary P. M., Roninson I. B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993 Apr 21;85(8):632–639. doi: 10.1093/jnci/85.8.632. [DOI] [PubMed] [Google Scholar]
  4. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  5. Elgie A. W., Sargent J. M., Williamson C. J., Lewandowicz G. M., Taylor C. G. Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML. Adv Exp Med Biol. 1999;457:29–33. doi: 10.1007/978-1-4615-4811-9_4. [DOI] [PubMed] [Google Scholar]
  6. Futscher B. W., Foley N. E., Gleason-Guzman M. C., Meltzer P. S., Sullivan D. M., Dalton W. S. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer. 1996 May 16;66(4):520–525. doi: 10.1002/(SICI)1097-0215(19960516)66:4<520::AID-IJC16>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  7. Hasinoff B. B., Hellmann K., Herman E. H., Ferrans V. J. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem. 1998 Feb;5(1):1–28. [PubMed] [Google Scholar]
  8. Kato S., Ideguchi H., Muta K., Nishimura J., Nawata H. Mechanisms involved in the development of adriamycin resistance in human leukemic cells. Leuk Res. 1990;14(6):567–573. doi: 10.1016/0145-2126(90)90009-x. [DOI] [PubMed] [Google Scholar]
  9. Kaye S. B. New drug development: its role in reversing drug resistance. Br J Cancer. 1999 Jul;80 (Suppl 1):116–121. [PubMed] [Google Scholar]
  10. Lemez P., Maresová J. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy. Semin Oncol. 1998 Aug;25(4 Suppl 10):61–65. [PubMed] [Google Scholar]
  11. Lucci A., Han T. Y., Liu Y. Y., Giuliano A. E., Cabot M. C. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer. 1999 Jul 15;86(2):300–311. doi: 10.1002/(sici)1097-0142(19990715)86:2<300::aid-cncr14>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  12. Sargent J. M., Taylor C. G. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia. Br J Cancer. 1989 Aug;60(2):206–210. doi: 10.1038/bjc.1989.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Scambia G., Della Bitta R., Benedetti Panici P., De Vincenzo R., Contu G., Ercoli A., Bonanno G., Pierelli L., Mancuso S. Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells. Gynecol Oncol. 1995 Apr;57(1):16–22. doi: 10.1006/gyno.1995.1094. [DOI] [PubMed] [Google Scholar]
  14. Sharpe H. B., Field E. O., Hellmann K. Mode of action of the cytostatic agent "ICRF 159". Nature. 1970 May 9;226(5245):524–526. doi: 10.1038/226524a0. [DOI] [PubMed] [Google Scholar]
  15. Sikic B. I., Fisher G. A., Lum B. L., Halsey J., Beketic-Oreskovic L., Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997;40 (Suppl):S13–S19. doi: 10.1007/s002800051055. [DOI] [PubMed] [Google Scholar]
  16. Swain S. M., Whaley F. S., Gerber M. C., Ewer M. S., Bianchine J. R., Gams R. A. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol. 1997 Apr;15(4):1333–1340. doi: 10.1200/JCO.1997.15.4.1333. [DOI] [PubMed] [Google Scholar]
  17. Synold T. W., Tetef M. L., Doroshow J. H. Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor. Semin Oncol. 1998 Aug;25(4 Suppl 10):93–99. [PubMed] [Google Scholar]
  18. Trock B. J., Leonessa F., Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1997 Jul 2;89(13):917–931. doi: 10.1093/jnci/89.13.917. [DOI] [PubMed] [Google Scholar]
  19. Weiss R. B. The randomized trials of dose-intensive therapy for breast cancer: what do they mean for patient care and where do we go from here? Oncologist. 1999;4(6):450–458. [PubMed] [Google Scholar]
  20. Yanagisawa T., Newman A., Coley H., Renshaw J., Pinkerton C. R., Pritchard-Jones K. BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer. 1999 Jun;80(8):1190–1196. doi: 10.1038/sj.bjc.6990485. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES